SUBLOCADE Strong Performance
SUBLOCADE net revenue increased 15% year-over-year and 5% sequentially, with improved commercial execution leading to solid dispense unit growth of 8% versus the prior year.
Raised Full Year 2025 Guidance
Indivior raised its 2025 financial guidance, expecting total net revenue to increase, driven by SUBLOCADE growth of 10% at the midpoint. Adjusted EBITDA guidance increased by 15% versus 2024 at the midpoint.
Significant Cost Reduction Initiatives
Strategic decisions are expected to result in at least $150 million in annual operating expense savings starting in 2026, including a 32% reduction in headcount.
Direct-to-Consumer Campaign Launch
A new direct-to-consumer campaign, 'Move Forward in Recovery,' was launched on October 1 to connect with patients and drive awareness of SUBLOCADE.
Stable SUBOXONE Film Pricing
SUBOXONE Film benefited from continued price stability in the U.S., contributing to the overall performance.